Pharmacology and safety of tofacitinib in ulcerative colitis

Gastroenterol Hepatol. 2021 Jan;44(1):39-48. doi: 10.1016/j.gastrohep.2020.04.012. Epub 2020 Aug 20.
[Article in English, Spanish]

Abstract

The use of Janus kinase (JAK) inhibitors is a new approach in the therapy of inflammatory diseases with immune base. Tofacitinib is one of these inhibitors targeting JAK1 and JAK3, and its efficacy has been demonstrated in the treatment of moderate to severe ulcerative colitis (UC). It is a small synthetic molecule administered orally, with a fast bioavailability and elimination rate, predictable pharmacokinetics and lack of immunogenicity, which are convenient characteristics for both efficacy and safety. This article reviews the pharmacological characteristics of tofacitinib and its safety profile.

Keywords: Colitis ulcerosa; Farmacología; JAK; Janus kinase; Pharmacology; Quinasas Janus; Safety; Seguridad; Tofacitinib; Ulcerative colitis.

Publication types

  • Review

MeSH terms

  • Arthritis, Rheumatoid
  • Colitis, Ulcerative / drug therapy*
  • Drug Interactions
  • Herpes Zoster / chemically induced
  • Herpes Zoster Vaccine / administration & dosage
  • Humans
  • Janus Kinase 1 / antagonists & inhibitors
  • Janus Kinase 3 / antagonists & inhibitors
  • Janus Kinase Inhibitors / adverse effects
  • Janus Kinase Inhibitors / pharmacokinetics
  • Janus Kinase Inhibitors / pharmacology*
  • Neoplasms / immunology
  • Piperidines / adverse effects
  • Piperidines / pharmacokinetics
  • Piperidines / pharmacology*
  • Pyrimidines / adverse effects
  • Pyrimidines / pharmacokinetics
  • Pyrimidines / pharmacology*
  • Venous Thromboembolism / chemically induced

Substances

  • Herpes Zoster Vaccine
  • Janus Kinase Inhibitors
  • Piperidines
  • Pyrimidines
  • tofacitinib
  • JAK1 protein, human
  • JAK3 protein, human
  • Janus Kinase 1
  • Janus Kinase 3